OCS · Oculis Holding AG · Metrics
Market Cap
$450.82M
Shares
61.59M
Volume · Oct 20
318.68K
Avg daily vol (3M)
265.89K
OCS metrics
65 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$7.49
Market cap
$450.82M
Price action
20 metricsPrice change (1W)
-7.1%
Price change (30D)
-27.8%
Price change (3M)
-37.6%
Price change (6M)
-74.4%
Price change (YTD)
-63.3%
Price change (1Y)
-66.3%
Trailing year
Price change (5Y)
-24.7%
52-week high
$32.65
52-week low
$7.17
Change from 52-week high
-77.6%
Change from 52-week low
+2.1%
Annualized volatility
66.9%
Annualized volatility (3M)
44.7%
Beta
1.1
RSI (14D)
24.0
Price vs SMA 50
-31.3%
Price vs SMA 200
-62.4%
Avg volume (3M)
264,971
Relative volume
1.1
Average dollar volume
$2.78M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
61.59M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
303.7×
reciprocal yield 0.3%
P / book
1.7
reciprocal yield 60.4%
FCF yield
-18.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-22.2%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
2026-11-05
Last earnings
2026-08-06
Profitability
9 metricsGross margin
—
Operating margin
-7,350.8%
Trailing 12 months
Net margin
-6,751.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$86.22M
Net income (TTM)
−$99.82M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-5,614.1%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+18.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.48M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
+9.5%
Revenue CAGR (5Y)
+3.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-36.1%
Return on assets
-31.6%
Debt / equity
—
Current ratio
8.3
EBITDA (TTM)
—
Free cash flow (TTM)
−$83.01M
Quick ratio
8.3
Interest coverage
-97.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$76.24M
Total assets
$309.74M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$82.78M
Capital expenditures (TTM)
$230,675
R&D (TTM)
$71.51M
SG&A (TTM)
—
Stock compensation (TTM)
$25.77M
R&D / revenue
4,836.7%
Stock compensation / revenue
1,742.9%
Ownership (13F)
9 metrics13F filers
65
13F filer change QoQ
+2
Institutional ownership
38.4%
Conviction holders (share of 13F filers)
8.5%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+31.5%
Holder tenure
4.8
Price vs estimated holder cost
-32.1%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.1%
Short interest
3 metricsShort interest
2.9%
Latest settlement · 6.5 days to cover
Days to cover
6.5d
Short-squeeze score
51 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—